BDMD vs ELMD vs NVCR vs LUNG

For growth investors, Baird Medical Investment Holdings Limited (BDMD) is the stronger pick with 17.

7% revenue growth year-over-year, versus 8. 0% for Pulmonx Corporation (LUNG). Baird Medical Investment Holdings Limited (BDMD) offers the better valuation at 3. 8x trailing P/E, making it the more compelling value choice. Analysts rate Electromed, Inc. (ELMD) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Baird Medical Investment Holdings Limited (BDMD) is the cheapest at 3.

8x versus Electromed, Inc. at 31. 2x.

Over the past 5 years, Electromed, Inc.

(ELMD) delivered a total return of +178. 1%, compared to -97. 0% for Pulmonx Corporation (LUNG). Over 10 years, the gap is even starker: ELMD returned +484. 2% versus LUNG's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Electromed, Inc.

(ELMD) is the lower-risk stock at 1. 01β versus Pulmonx Corporation's 2. 31β — meaning LUNG is approximately 129% more volatile than ELMD relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 104% for Pulmonx Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Baird Medical Investment Holdings Limited (BDMD) is pulling ahead at 17.

7% versus 8. 0% for Pulmonx Corporation (LUNG). On earnings-per-share growth, the picture is similar: Electromed, Inc. grew EPS 48. 3% year-over-year, compared to 7. 6% for Pulmonx Corporation. Over a 3-year CAGR, LUNG leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Baird Medical Investment Holdings Limited (BDMD) is the more profitable company, earning 33.

6% net margin versus -59. 7% for Pulmonx Corporation — meaning it keeps 33. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDMD leads at 41. 4% versus -59. 3% for LUNG. At the gross margin level — before operating expenses — BDMD leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Electromed, Inc.

(ELMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 01), +484. 2% 10Y return). Pulmonx Corporation (LUNG) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELMD: +484. 2%, LUNG: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BDMD is a small-cap high-growth stock; ELMD is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; LUNG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.